골수침습 치료저항 변연부B세포림프종과 치료 관련 골수형성이상증후군이 골수에 공존한 1예
A Case of Coexistence of Bone Marrow-involved Refractory Marginal Zone B-Cell Lymphoma and Therapy-related Myelodysplastic Syndrome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
최신 항암화학요법의 발전이 악성림프종 등 혈액암 환자들의 생존율을 증가시켰으나 알킬화약물을 포함한 비호지킨림프종에 대한 표준 화학요법은, 2008년 WHO 분류에 의거한 치료 관련 골수종양을 유발할 수 있다. 저자들은 골수침습 치료저항 변연부B세포림프종과 치료 관련 골수형성이상증후군이 골수에 공존한 한 예를 보고하는 바이다. 골수에 치료저항 림프종과 치료 관련 골수형성이상증후군이 동시에 존재하는 것은 드문 일이며, 본 예가 한국에서 보고하는 첫 예로 여겨진다. 변연부B세포림프종과 치료 관련 골수형성이상증후군 양쪽 모두를 치료하기 위하여 환자는 동종조혈모세포이식을 받았으며 이후 21개월째 재발의 증거 없이 안정 상태를 유지하고 있다.
Abstract
Recent advances in chemotherapy have led to increased survival rates for patients with hematologic malignancies. However, standard chemotherapies, including alkylating agents for non-Hodgkin lymphoma, could induce therapy-related myeloid neoplasms (t-MNs), a group of disorders categorized by the World Health Organization in 2008. Here, we report a case of coexistence of bone marrow (BM)-involved refractory marginal zone B-cell lymphoma (MZL) and therapy-related myelodysplastic syndrome (t-MDS). Simultaneous presence of refractory lymphoma and t-MN in the BM is rare, and this is the first report in Korea. The patient received allogeneic hematopoietic stem cell transplantation (HSCT) to cure both the MZL and t-MDS. Since the HSCT, he has been stable for 21 months without any evidence of recurrence.
참고문헌 (12)
- Larson RA, "Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms", J Clin Oncol, 30, pp.2300~2302 (2012)
- Friedberg JW, "Secondary malignancies after therapy of indolent non-Hodgkin’s lymphoma", Haematologica, 93, pp.336~338 (2008)
- Shimura Y, "Reduced-intensity allogeneic stem cell transplantation for co-emergence of chemotherapy-refractory follicular lymphoma and therapy-related myelodysplastic syndrome", Case Rep Oncol, 7, pp.188~194 (2014)
- Morton LM, "Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008", Blood, 121, pp.2996~3004 (2013)
- Greenberg PL, "Revised international prognostic scoring system for myelodysplastic syndromes", Blood, 120, pp.2454~2465 (2012)
- Zhang L, "A focused review of hematopoietic neoplasms occurring in the therapy-related setting", Int J Clin Exp Pathol, 7, pp.3512~3523 (2014)
- Niscola P, "Complex and multifaceted therapy-related myeloid neoplasm following laryngeal cancer treated with Cisplatin and radiotherapy", Mediterr J Hematol Infect Dis, 5, pp.e2013030~ (2013)
- Candelaria M, "Therapy-related myelodysplastic syndrome", Expert Opin Drug Saf, 14, pp.655~665 (2015)
- Kang HJ, "Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: consortium for Improving Survival of Lymphoma (CISL) study", Ann Hematol, 91, pp.543~551 (2012)
- Hyeon Jin Park, "Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008", Blood Research, 47(1), pp.28~38 (2012), 대한혈액학회
- Li L, "High-dose therapy", autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma, 2011, pp.11, 253~256
- Zimmerman Z, "Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy", Bone Marrow Transplant, 47, pp.804~809 (2012)